Evidence map›Paper›PMID 36324999›Full record

ArticleClinical kidney journal2022

Gain-of-function

Priscila Villalvazo, Sol Carriazo, Jorge Rojas-Rivera, Adrián M Ramos, Alberto Ortiz, Maria Vanessa Perez-Gomez

Abstract readEditorial
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. A20 in Kidney Transplantation and Autoimmunity.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Priscila VillalvazoDepartment of Nephrology and Hypertension, Instituto de Investigación Sanitaria, Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.ORCID https://orcid.org/0000-0001-9359-1812
Sol CarriazoDepartment of Nephrology and Hypertension, Instituto de Investigación Sanitaria, Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.
Jorge Rojas-RiveraDepartment of Nephrology and Hypertension, Instituto de Investigación Sanitaria, Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.
Adrián M RamosDepartment of Nephrology and Hypertension, Instituto de Investigación Sanitaria, Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.
Alberto OrtizDepartment of Nephrology and Hypertension, Instituto de Investigación Sanitaria, Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.ORCID https://orcid.org/0000-0002-9805-9523
Maria Vanessa Perez-GomezDepartment of Nephrology and Hypertension, Instituto de Investigación Sanitaria, Fundacion Jimenez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.ORCID https://orcid.org/0000-0003-4558-5236

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a chronic and inflammatory autoimmune disease of unknown origin that may cause kidney disease, i.e. lupus nephritis (LN). Within a wider trend towards an expanding field of genetic causes of kidney disease, two recent reports have emphasized the role of Mendelian autoimmune disorders in causing LN both in children and in young adults. Loss-of-function (LOF) variants of tumor necrosis factor alpha-induced protein 3 (

Indexed as

A20HA20inherited kidney diseaselupus nephritissystemic lupus erythematosusTLR7

Identifiers

PMID36324999
PMCPMC9613427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.